BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanguine Corporation (SGNC) Subsidiary to Change Name From Sanguine Life Sciences to SGN Life Sciences


10/6/2009 10:52:46 AM

PASADENA, CA--(Marketwire - October 06, 2009) - Sanguine Corp (OTCBB: SGUI) announced today that it will change the name of its wholly-owned subsidiary, Sanguine Life Sciences, to SGN Life Sciences. The Company explained that the name change is necessary to better reflect the subsidiary's intended business model. Company spokesperson, Mr. Frank Marra, explained, "When we decided to set up the Sanguine Life Sciences subsidiary we did so primarily for the purpose of seeking partnering relationships or merger candidates for PHER-O2. However, it has become clear that the scope of the subsidiary can represent much more opportunity to the Company. We intend to use the SGN Subsidiary to take advantage of market opportunities that have presented themselves to us; which includes, but is not limited to, PHER-O2 potential collaborations. Quite frankly, we are seeking, and have been in conversations with, potential partnership, merger and/or acquisition candidates that can move the Company towards revenue generation."

Mr. Marra added, "In recent months we have been actively working to find the proper relationship to assist us in taking PHER-O2 to the next level. We believe that there are a number of very exciting opportunities for PHER-O2 in the marketplace and we are in the process of determining the best possible partner, or partners, for us."

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Contact:
For Sanguine Corporation
Michael Dancy
801-746-3570 (Investor Relations)
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES